Applied Therapeutics (APLT) to Release Earnings on Thursday

Applied Therapeutics (NASDAQ:APLT) is expected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:00 PM ET.

Applied Therapeutics (NASDAQ:APLT) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.02. On average, analysts expect Applied Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Applied Therapeutics Price Performance

APLT stock opened at $1.22 on Thursday. The company has a 50 day moving average price of $0.79 and a 200 day moving average price of $0.54. Applied Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $10.62. The stock has a market capitalization of $175.69 million, a PE ratio of -2.71 and a beta of 2.07.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Applied Therapeutics stock. Marshall Wace LLP boosted its position in shares of Applied Therapeutics Inc. (NASDAQ:APLT) by 18.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,544,191 shares of the company’s stock after purchasing an additional 236,810 shares during the quarter. Marshall Wace LLP owned 1.09% of Applied Therapeutics worth $479,000 as of its most recent SEC filing. Institutional investors own 98.31% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on APLT. Weiss Ratings reissued a “sell (e+)” rating on shares of Applied Therapeutics in a research note on Tuesday, October 14th. Wall Street Zen upgraded Applied Therapeutics to a “sell” rating in a report on Saturday, July 26th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $4.13.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.